Combined use of PRAME inhibitors and HDAC inhibitors

摘要

The invention relates to the cancer antigen PRAME (PReferentially expressed Antigen in MElanoma) and its use in a method of treatment of a tumour which comprises administerin to a subject in need of treatment an effective amount of an inhibitor of PRAME in combination with a second agent selected from the group of an inhibitor of HDAC (an HDACi) and a retinoid.